Education
About Us
Working with TipRanks
Follow Us
Bg Medicine (BGMD)
OTHER OTC:BGMD
BGMD Stock Chart & Stats
$0.02
$0.00(0.00%)
At close: 4:00 PM EST
$0.02
$0.00(0.00%)
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
Volume5.91K
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BGMD FAQ
What was Bg Medicine’s price range in the past 12 months?
Currently, no data Available
What is Bg Medicine’s market cap?
Currently, no data Available
When is Bg Medicine’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Bg Medicine’s earnings last quarter?
Currently, no data Available
Is Bg Medicine overvalued?
According to Wall Street analysts Bg Medicine’s price is currently Overvalued.
Does Bg Medicine pay dividends?
Bg Medicine does not currently pay dividends.
What is Bg Medicine’s EPS estimate?
Bg Medicine’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bg Medicine have?
Currently, no data Available
What happened to Bg Medicine’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Bg Medicine?
Currently, no hedge funds are holding shares in BGMD
Company Description
Bg Medicine
BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.